Overview

• Initial Phase 1b trial data for Verve-102 demonstrated significant LDL cholesterol reductions, with a maximum reduction of 69% in some patients.
• The therapy targets the PCSK9 gene in the liver, using an improved lipid nanoparticle delivery system developed in-house to address prior safety concerns.
• All 14 trial participants tolerated the treatment well, with no serious adverse events or significant laboratory abnormalities reported.
• The U.S. FDA recently granted Fast Track designation to Verve-102, recognizing its potential to address hyperlipidemia and cardiovascular risks.
• Verve plans to begin Phase 2 trials in the second half of 2025, with ongoing collaboration with Eli Lilly on global development and commercialization.